Rapamycin protects against Aβ-induced synaptotoxicity by increasing presynaptic activity in hippocampal neurons

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1495-1501

  Ramirez A E ^a   Pacheco, C R ^a   Aguayo, L G ^a   Opazo, C M ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; A oligomer; Rapamycin; SV2; Synaptic activity; Synaptotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; MAMMALIAN TARGET OF RAPAMYCIN; OLIGOMER; PRESYNAPTIC RECEPTOR; RAPAMYCIN; AMYLOID BETA PROTEIN[1-42]; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; POSTSYNAPTIC DENSITY PROTEIN 95; POSTSYNAPTIC RECEPTOR; PROTEIN; PROTEIN SV2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; NERVE CELL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOTOXICITY; UPREGULATION; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; EXOCYTOSIS; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; LONG TERM POTENTIATION; NEUROMODULATION; NEUROTRANSMISSION; PRESYNAPTIC POTENTIAL; PROTEIN SYNTHESIS; SYNAPSE VESICLE; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; AΒ OLIGOMER; RAPAMYCIN; SV2; SYNAPTIC ACTIVITY; SYNAPTOTOXICITY;

AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CELL PROLIFERATION; CELLS, CULTURED; EXCITATORY POSTSYNAPTIC POTENTIALS; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SYNAPTIC TRANSMISSION;

EID: 84903459372     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.019     Document Type: Article

References (54)

1. Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 2007, 6:304-312.
2. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
3. Swiech L., Perycz M., Malik A., Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim. Biophys. Acta 2008, 1784:116-132.
4. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010, 33:67-75.
5. Abel T., Lattal K.M. Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr. Opin. Neurobiol. 2001, 11:180-187.
6. Tang S.J., Reis G., Kang H., Gingras A.C., Sonenberg N., Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:467-472.
7. Hernandez D., Torres C.A., Setlik W., Cebrian C., Mosharov E.V., Tang G., Cheng H.C., Kholodilov N., Yarygina O., Burke R.E., Gershon M., Sulzer D. Regulation of presynaptic neurotransmission by macroautophagy. Neuron 2012, 74:277-284.
8. Shen W., Ganetzky B. Autophagy promotes synapse development in Drosophila. J. Cell Biol. 2009, 187:71-79.
9. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 2003, 35:7S-14S.
10. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
11. Miller R.A., Harrison D.E., Astle C.M., Baur J.A., Boyd A.R., de Cabo R., Fernandez E., Flurkey K., Javors M.A., Nelson J.F., Orihuela C.J., Pletcher S., Sharp Z.D., Sinclair D., Starnes J.W., Wilkinson J.E., Nadon N.L., Strong R. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:191-201.
12. Santos R.X., Correia S.C., Cardoso S., Carvalho C., Santos M.S., Moreira P.I. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease. J. Neurochem. 2011, 117:927-936.
13. Cai Z., Yan L.J. Rapamycin, autophagy, and Alzheimer's disease. J. Biochem. Pharmacol. Res. 2013, 1:84-90.
14. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848.
15. Costa-Mattioli M., Monteggia L.M. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat. Neurosci. 2013, 16:1537-1543.
16. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e9979.
17. Findeis M.A. The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol. Ther. 2007, 116:266-286.
18. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events. Mol. Neurodegener. 2009, 4:14.
19. Caccamo A., Maldonado M.A., Majumder S., Medina D.X., Holbein W., Magri A., Oddo S. Naturally secreted amyloid-β increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J. Biol. Chem. 2011, 286:8924-8932.
20. Parodi J., Sepulveda F.J., Roa J., Opazo C., Inestrosa N.C., Aguayo L.G. β-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J. Biol. Chem. 2010, 285:2506-2514.
21. Sepulveda F.J., Parodi J., Peoples R.W., Opazo C., Aguayo L.G. Synaptotoxicity of Alzheimer β amyloid can be explained by its membrane perforating property. PLoS One 2010, 5:e11820.
22. Peters C., Fernandez-Perez E.J., Burgos C.F., Espinoza M.P., Castillo C., Urrutia J.C., Streltsov V.A., Opazo C., Aguayo L.G. Inhibition of amyloid β-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide. Neurobiol. Aging 2013, 34:2805-2814.
23. Tapia J.C., Mentis G.Z., Navarrete R., Nualart F., Figueroa E., Sanchez A., Aguayo L.G. Early expression of glycine and GABA(A) receptors in developing spinal cord neurons. Effects on neurite outgrowth. Neuroscience 2001, 108:493-506.
24. Garrido J.L., Godoy J.A., Alvarez A., Bronfman M., Inestrosa N.C. Protein kinase C inhibits amyloid β peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 2002, 16:1982-1984.
25. Henry F.E., McCartney A.J., Neely R., Perez A.S., Carruthers C.J., Stuenkel E.L., Inoki K., Sutton M.A. Retrograde changes in presynaptic function driven by dendritic mTORC1. J. Neurosci. 2012, 32:17128-17142.
26. Gu X., Olson E.C., Spitzer N.C. Spontaneous neuronal calcium spikes and waves during early differentiation. J. Neurosci. 1994, 14:6325-6335.
27. Terry R.D. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2000, 59:1118-1119.
28. Chauhan N.B., Siegel G.J. Reversal of amyloid β toxicity in Alzheimer's disease model Tg2576 by intraventricular anti-amyloid β antibody. J. Neurosci. Res. 2002, 69:10-23.
29. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell W., Kaye J., Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis. 2005, 7:103-117. (discussion 173-180).
30. Sepulveda F.J., Opazo C., Aguayo L.G. Alzheimer β-amyloid blocks epileptiform activity in hippocampal neurons. Mol. Cell. Neurosci. 2009, 41:420-428.
31. Halloran J., Hussong S., Burbank R., Podlutskaya N., Fischer K., Sloane L., Austad S.N., Strong R., Richardson A., Hart M., Galvan V. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012, 223:102-113.
32. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-β, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
33. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
34. Terashima A., Nakai M., Hashimoto T., Kawamata T., Taniguchi T., Yasuda M., Maeda K., Tanaka C. Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin. Brain Res. 1998, 786:255-258.
35. Kavalali E.T. Multiple vesicle recycling pathways in central synapses and their impact on neurotransmission. J. Physiol. 2007, 585:669-679.
36. Terashima A., Taniguchi T., Nakai M., Yasuda M., Kawamata T., Tanaka C. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons. Neuropharmacology 2000, 39:1920-1928.
37. Puighermanal E., Marsicano G., Busquets-Garcia A., Lutz B., Maldonado R., Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat. Neurosci. 2009, 12:1152-1158.
38. Lafay-Chebassier C., Paccalin M., Page G., Barc-Pain S., Perault-Pochat M.C., Gil R., Pradier L., Hugon J. mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J. Neurochem. 2005, 94:215-225.
39. Morel M., Couturier J., Pontcharraud R., Gil R., Fauconneau B., Paccalin M., Page G. Evidence of molecular links between PKR and mTOR signalling pathways in Aβ neurotoxicity: role of p53, Redd1 and TSC2. Neurobiol. Dis. 2009, 36:151-161.
40. Cammalleri M., Lutjens R., Berton F., King A.R., Simpson C., Francesconi W., Sanna P.P. Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14368-14373.
41. Bove J., Martinez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 2011, 12:437-452.
42. Pierce A., Podlutskaya N., Halloran J.J., Hussong S.A., Lin P.Y., Burbank R., Hart M.J., Galvan V. Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease. J. Neurochem. 2013, 124:880-893.
43. Vossel K.A., Beagle A.J., Rabinovici G.D., Shu H., Lee S.E., Naasan G., Hegde M., Cornes S.B., Henry M.L., Nelson A.B., Seeley W.W., Geschwind M.D., Gorno-Tempini M.L., Shih T., Kirsch H.E., Garcia P.A., Miller B.L., Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013, 70:1158-1166.
44. Amatniek J.C., Hauser W.A., DelCastillo-Castaneda C., Jacobs D.M., Marder K., Bell K., Albert M., Brandt J., Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006, 47:867-872.
45. Lozsadi D.A., Larner A.J. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 22:121-124.
46. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
47. Palop J.J., Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
48. Tampellini D., Rahman N., Gallo E.F., Huang Z., Dumont M., Capetillo-Zarate E., Ma T., Zheng R., Lu B., Nanus D.M., Lin M.T., Gouras G.K. Synaptic activity reduces intraneuronal Aβ, promotes APP transport to synapses, and protects against Aβ-related synaptic alterations. J. Neurosci. 2009, 29:9704-9713.
49. Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26:1235-1244.
50. Zhang S.J., Buchthal B., Lau D., Hayer S., Dick O., Schwaninger M., Veltkamp R., Zou M., Weiss U., Bading H. A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage. J. Neurosci. 2011, 31:4978-4990.
51. Hoey S.E., Williams R.J., Perkinton M.S. Synaptic NMDA receptor activation stimulates α-secretase amyloid precursor protein processing and inhibits amyloid-β production. J. Neurosci. 2009, 29:4442-4460.
52. Wang Z.C., Zhao J., Li S. Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β. Neurosci. Bull. 2013, 29:752-760.
53. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., Sawyers C.L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5:e8.
54. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.